New Procedure Halts Weight Regain Post-Ozempic

Researchers have developed a new, minimally invasive procedure that could offer a solution for individuals seeking to maintain weight loss after discontinuing medications such as Ozempic and semaglutide. This addresses a significant challenge in the weight-loss drug industry, where most patients regain weight after stopping treatment.

The procedure, known as duodenal mucosal resurfacing (DMR), uses controlled heat to renew the lining of the upper small intestine. This is believed to help reset metabolism and prevent the common weight regain experienced by nearly 70% of individuals within 18 months of stopping GLP-1 medications.

A clinical trial involving 45 patients who had lost an average of 40 pounds found that those who underwent DMR maintained over 80% of their weight loss six months after discontinuing their medication. In contrast, a control group that received a sham treatment regained more weight, suggesting DMR's benefit may increase over time.

The DMR procedure targets the duodenum, the initial part of the small intestine, which plays a crucial role in producing hormones that regulate appetite and metabolism. By ablating damaged mucosal lining caused by unhealthy diets, the procedure stimulates the regrowth of healthy tissue, aiding in weight maintenance.

While the procedure is still investigational and awaiting FDA approval, a larger trial named REMAIN-1, with over 300 participants, is currently underway. Topline results are anticipated in early Q4 2026, potentially paving the way for duodenal mucosal resurfacing to become a vital "off-ramp" for patients using GLP-1 weight-loss drugs.